INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
7.77
-0.30 (-3.72%)
At close: Apr 3, 2025, 4:00 PM
7.74
-0.03 (-0.44%)
Pre-market: Apr 4, 2025, 4:05 AM EDT
INmune Bio Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for INmune Bio stock have an average target of 24.33, with a low estimate of 20 and a high estimate of 30. The average target predicts an increase of 213.13% from the current stock price of 7.77.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 13, 2025.
Analyst Ratings
The average analyst rating for INmune Bio stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $22 → $30 | Strong Buy | Maintains | $22 → $30 | +286.10% | Feb 13, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $22 → $23 | Buy | Maintains | $22 → $23 | +196.01% | Feb 11, 2025 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +157.40% | Oct 21, 2024 |
| Scotiabank | Scotiabank | Buy Initiates $22 | Buy | Initiates | $22 | +183.14% | Aug 22, 2024 |
| Baird | Baird | Buy Initiates $16 | Buy | Initiates | $16 | +105.92% | Jun 1, 2023 |
Financial Forecast
Revenue This Year
n/a
from 14.00K
Revenue Next Year
6.61M
EPS This Year
-1.96
from -2.11
EPS Next Year
-1.68
from -1.96
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 15.2M | 25.5M | ||
| Avg | n/a | 6.6M | 15.1M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 285.9% | ||
| Avg | - | - | 127.8% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.62 | -1.30 | 2.79 | ||
| Avg | -1.96 | -1.68 | -0.73 | ||
| Low | -2.32 | -1.95 | -1.86 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.